<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">35174650</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>25</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2052-1707</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>2</Issue><PubDate><Year>2022</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Pharmacology research &amp; perspectives</Title><ISOAbbreviation>Pharmacol Res Perspect</ISOAbbreviation></Journal><ArticleTitle>Chronic cerebral aspects of long COVID, post-stroke syndromes and similar states share their pathogenesis and perispinal etanercept treatment logic.</ArticleTitle><Pagination><StartPage>e00926</StartPage><MedlinePgn>e00926</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e00926</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/prp2.926</ELocationID><Abstract><AbstractText>The chronic neurological aspects of traumatic brain injury, post-stroke syndromes, long COVID-19, persistent Lyme disease, and influenza encephalopathy having close pathophysiological parallels that warrant being investigated in an integrated manner. A mechanism, common to all, for this persistence of the range of symptoms common to these conditions is described. While TNF maintains cerebral homeostasis, its excessive production through either pathogen-associated molecular patterns or damage-associated molecular patterns activity associates with the persistence of the symptoms common across both infectious and non-infectious conditions. The case is made that this shared chronicity arises from a positive feedback loop causing the persistence of the activation of microglia by the TNF that these cells generate. Lowering this excess TNF is the logical way to reducing this persistent, TNF-maintained, microglial activation. While too large to negotiate the blood-brain barrier effectively, the specific anti-TNF biological, etanercept, shows promise when administered by the perispinal route, which allows it to bypass this obstruction.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors. Pharmacology Research &amp; Perspectives published by British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics and John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Clark</LastName><ForeName>Ian Albert</ForeName><Initials>IA</Initials><Identifier Source="ORCID">0000-0003-1945-0370</Identifier><AffiliationInfo><Affiliation>Research School of Biology, Australian National University, Canberra, ACT, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Pharmacol Res Perspect</MedlineTA><NlmUniqueID>101626369</NlmUniqueID><ISSNLinking>2052-1707</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>OP401G7OJC</RegistryNumber><NameOfSubstance UI="D000068800">Etanercept</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Pharmacol Res Perspect. 2022 Apr;10(2):e00942. doi: 10.1002/prp2.942</RefSource><PMID Version="1">35246965</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068800" MajorTopicYN="N">Etanercept</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007278" MajorTopicYN="N">Injections, Spinal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020521" MajorTopicYN="N">Stroke</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013577" MajorTopicYN="N">Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">TNF</Keyword><Keyword MajorTopicYN="N">chronicity of neurological deficit</Keyword><Keyword MajorTopicYN="N">etanercept</Keyword><Keyword MajorTopicYN="N">fatigue</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">post-stroke syndromes</Keyword><Keyword MajorTopicYN="N">taste and smell</Keyword></KeywordList><CoiStatement>The author declares no conflict of interest or financial involvement in the research discussed here.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>1</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>1</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>2</Month><Day>17</Day><Hour>5</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>2</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>2</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35174650</ArticleId><ArticleId IdType="pmc">PMC8850677</ArticleId><ArticleId IdType="doi">10.1002/prp2.926</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Clark IA, Virelizier J&#x2010;L, Carswell EA, Wood PR. Possible importance of macrophage&#x2010;derived mediators in acute malaria. Infect Immun. 1981;32:1058&#x2010;1066.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC351558</ArticleId><ArticleId IdType="pubmed">6166564</ArticleId></ArticleIdList></Reference><Reference><Citation>Janeway CA Jr. Pillars article: approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol. 1989;54:1&#x2010;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">24141854</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallucci S, Matzinger P. Danger signals: SOS to the immune system. Curr Opin Immunol. 2001;13:114&#x2010;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">11154927</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark IA, Vissel B. Amyloid beta: one of three danger&#x2010;associated molecules that are secondary inducers of the proinflammatory cytokines that mediate Alzheimer's disease. Br J Pharmacol. 2015;172:3714&#x2010;3727.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4523330</ArticleId><ArticleId IdType="pubmed">25939581</ArticleId></ArticleIdList></Reference><Reference><Citation>Spriggs DR, Sherman ML, Michie H, et al. Recombinant human tumor necrosis factor administered as a 24&#x2010;hour intravenous infusion. A phase 1 and pharmacologic study. J Natl Cancer Inst. 1988;80:1039&#x2010;1044.</Citation><ArticleIdList><ArticleId IdType="pubmed">3411618</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinmetz T, Schaadt M, G&#xe4;hl R, Schenk V, Diehl V, Pfreundschuh M. Phase 1 study of 24&#x2010;hour continuous intravenous infusion of recombinant human tumor necrosis factor. J Biol Resp Mod. 1988;7:417&#x2010;423.</Citation><ArticleIdList><ArticleId IdType="pubmed">3183683</ArticleId></ArticleIdList></Reference><Reference><Citation>Rauthe G, Sistermanns J. Recombinant tumour necrosis factor in the local therapy of malignant pleural effusion. Eur J Cancer. 1997;33:226&#x2010;231.</Citation><ArticleIdList><ArticleId IdType="pubmed">9135493</ArticleId></ArticleIdList></Reference><Reference><Citation>Lillie PJ, Duncan CJ, Sheehy SH, et al. Distinguishing malaria and influenza: early clinical features in controlled human experimental infection studies. Travel Med Infect Dis. 2012;10:192&#x2010;196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3778896</ArticleId><ArticleId IdType="pubmed">22531678</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M, Wang L, Guo Y, et al. A high mobility group box 1 (HMGB1) gene from Chlamys farreri and the DNA&#x2010;binding ability and pro&#x2010;inflammatory activity of its recombinant protein. Fish Shellfish Immunol. 2014;36:393&#x2010;400.</Citation><ArticleIdList><ArticleId IdType="pubmed">24378681</ArticleId></ArticleIdList></Reference><Reference><Citation>Rider P, Voronov E, Dinarello CA, Apte RN, Cohen I. Alarmins: feel the stress. J Immunol. 2017;198:1395&#x2010;1402.</Citation><ArticleIdList><ArticleId IdType="pubmed">28167650</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, Yu B, Yang P. Hypoxia&#x2010;induced HMGB1 in wound tissues promotes the osteoblast cell proliferation via activating ERK/JNK signaling. Int J Clin Exp Med. 2015;8:15087&#x2010;15097.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4658881</ArticleId><ArticleId IdType="pubmed">26628992</ArticleId></ArticleIdList></Reference><Reference><Citation>Willenbrock S, Braun O, Baumgart J, et al. TNF&#x2010;&#x3b1; induced secretion of HMGB1 from non&#x2010;immune canine mammary epithelial cells (MTH53A). Cytokine. 2012;57:210&#x2010;220.</Citation><ArticleIdList><ArticleId IdType="pubmed">22154216</ArticleId></ArticleIdList></Reference><Reference><Citation>Hreggvidsdottir HS, Ostberg T, Wahamaa H, et al. The alarmin HMGB1 acts in synergy with endogenous and exogenous danger signals to promote inflammation. J Leukoc Biol. 2009;86:655&#x2010;662.</Citation><ArticleIdList><ArticleId IdType="pubmed">19564572</ArticleId></ArticleIdList></Reference><Reference><Citation>Moniuszko&#x2010;Malinowska A, Penza P, Czupryna P, et al. Assessment of HMGB&#x2010;1 concentration in tick&#x2010;borne encephalitis and neuroborreliosis. Int J Infect Dis. 2018;70:131&#x2010;136.</Citation><ArticleIdList><ArticleId IdType="pubmed">29559369</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersson U, Ottestad W, Tracey KJ. Extracellular HMGB1: a therapeutic target in severe pulmonary inflammation including COVID&#x2010;19? Mol Med. 2020;26:42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7203545</ArticleId><ArticleId IdType="pubmed">32380958</ArticleId></ArticleIdList></Reference><Reference><Citation>Alleva LM, Budd AC, Clark IA. Systemic release of high mobility group box 1 protein during severe murine influenza. J Immunol. 2008;181:1454&#x2010;1459.</Citation><ArticleIdList><ArticleId IdType="pubmed">18606700</ArticleId></ArticleIdList></Reference><Reference><Citation>Terrando N, Yang T, Wang X, et al. Systemic HMGB1 neutralization prevents postoperative neurocognitive dysfunction in aged rats. Front Immunol. 2016;7:441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5075578</ArticleId><ArticleId IdType="pubmed">27822212</ArticleId></ArticleIdList></Reference><Reference><Citation>Parker TM, Nguyen AH, Rabang JR, Patil AA, Agrawal DK. The danger zone: systematic review of the role of HMGB1 danger signalling in traumatic brain injury. Brain Inj. 2017;31:2&#x2010;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5610113</ArticleId><ArticleId IdType="pubmed">27819487</ArticleId></ArticleIdList></Reference><Reference><Citation>He HJ, Wang Y, Le Y, et al. Surgery upregulates high mobility group box&#x2010;1 and disrupts the blood&#x2010;brain barrier causing cognitive dysfunction in aged rats. CNS Neurosci Ther. 2012;18:994&#x2010;1002.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6493557</ArticleId><ArticleId IdType="pubmed">23078219</ArticleId></ArticleIdList></Reference><Reference><Citation>Faraco G, Fossati S, Bianchi ME, et al. High mobility group box 1 protein is released by neural cells upon different stresses and worsens ischemic neurodegeneration in vitro and in vivo. J Neurochem. 2007;103:590&#x2010;603.</Citation><ArticleIdList><ArticleId IdType="pubmed">17666052</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu M, Zhou GM, Wang LH, et al. Inhibiting high&#x2010;mobility group box 1 (HMGB1) attenuates inflammatory cytokine expression and neurological deficit in ischemic brain injury following cardiac arrest in rats. Inflammation. 2016;39:1594&#x2010;1602.</Citation><ArticleIdList><ArticleId IdType="pubmed">27363991</ArticleId></ArticleIdList></Reference><Reference><Citation>Quistad SD, Stotland A, Barott KL, et al. Evolution of TNF&#x2010;induced apoptosis reveals 550 My of functional conservation. Proc Natl Acad Sci USA. 2014;111:9567&#x2010;9572.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4084427</ArticleId><ArticleId IdType="pubmed">24927546</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong S, Li R, Xu Q, Secombes CJ, Wang T. Two types of TNF&#x2010;alpha exist in teleost fish: phylogeny, expression, and bioactivity analysis of Type&#x2010;II TNF&#x2010;alpha3 in rainbow trout Oncorhynchus mykiss . J Immunol. 2013;197:5959&#x2010;5972.</Citation><ArticleIdList><ArticleId IdType="pubmed">24244011</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam FW, Wu SY, Lin SJ, et al. The expression of two novel orange&#x2010;spotted grouper (Epinephelus coioides) TNF genes in peripheral blood leukocytes, various organs, and fish larvae. Fish Shellfish Immunol. 2011;30:618&#x2010;629.</Citation><ArticleIdList><ArticleId IdType="pubmed">21195186</ArticleId></ArticleIdList></Reference><Reference><Citation>Vitkovic L, Bockaert J, Jacque C. &#x2018;Inflammatory&#x2019; cytokines: neuromodulators in normal brain? J Neurochem. 2000;74:457&#x2010;471.</Citation><ArticleIdList><ArticleId IdType="pubmed">10646496</ArticleId></ArticleIdList></Reference><Reference><Citation>Gavalda N, Gutierrez H, Davies AM. Developmental regulation of sensory neurite growth by the tumor necrosis factor superfamily member LIGHT. J Neurosci. 2009;29:1599&#x2010;1607.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6666283</ArticleId><ArticleId IdType="pubmed">19211867</ArticleId></ArticleIdList></Reference><Reference><Citation>Wheeler MA, Heffner DL, Kim S, et al. TNF&#x2010;alpha/TNFR1 signaling is required for the development and function of primary nociceptors. Neuron. 2014;82:587&#x2010;602.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4046273</ArticleId><ArticleId IdType="pubmed">24811380</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu B, Zupan B, Laird E, et al. Maternal hematopoietic TNF, via milk chemokines, programs hippocampal development and memory. Nat Neurosci. 2014;17:97&#x2010;105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6169993</ArticleId><ArticleId IdType="pubmed">24292233</ArticleId></ArticleIdList></Reference><Reference><Citation>Marin I, Kipnis J. Learning and memory &#x2026; and the immune system. Learn Mem. 2013;20:601&#x2010;606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3768198</ArticleId><ArticleId IdType="pubmed">24051097</ArticleId></ArticleIdList></Reference><Reference><Citation>Camara ML, Corrigan F, Jaehne EJ, Jawahar MC, Anscomb H, Baune BT. Tumor necrosis factor alpha and its receptors in behaviour and neurobiology of adult mice, in the absence of an immune challenge. Behav Brain Res. 2015;290:51&#x2010;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">25934492</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark IA, Vissel B. Excess cerebral TNF causing glutamate excitotoxicity rationalizes treatment of neurodegenerative diseases and neurogenic pain by anti&#x2010;TNF agents. J Neuroinflammation. 2016;13:236.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5011997</ArticleId><ArticleId IdType="pubmed">27596607</ArticleId></ArticleIdList></Reference><Reference><Citation>Pickering M, Cumiskey D, O'Connor JJ. Actions of TNF&#x2010;alpha on glutamatergic synaptic transmission in the central nervous system. Exp Physiol. 2005;90:663&#x2010;670.</Citation><ArticleIdList><ArticleId IdType="pubmed">15944202</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferguson AR, Christensen RN, Gensel JC, et al. Cell death after spinal cord injury is exacerbated by rapid TNFalpha&#x2010;induced trafficking of GluR2&#x2010;lacking AMPARs to the plasma membrane. J Neurosci. 2008;28:11391&#x2010;11400.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2598739</ArticleId><ArticleId IdType="pubmed">18971481</ArticleId></ArticleIdList></Reference><Reference><Citation>Stellwagen D, Malenka RC. Synaptic scaling mediated by glial TNF&#x2010;alpha. Nature. 2006;440:1054&#x2010;1059.</Citation><ArticleIdList><ArticleId IdType="pubmed">16547515</ArticleId></ArticleIdList></Reference><Reference><Citation>Cumiskey D, Butler MP, Moynagh PN, O'Connor JJ. Evidence for a role for the group I metabotropic glutamate receptor in the inhibitory effect of tumor necrosis factor&#x2010;alpha on long&#x2010;term potentiation. Brain Res. 2007;1136:13&#x2010;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">17198691</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernardino L, Agasse F, Silva B, Ferreira R, Grade S, Malva JO. Tumor necrosis factor&#x2010;alpha modulates survival, proliferation, and neuronal differentiation in neonatal subventricular zone cell cultures. Stem Cells. 2008;26:2361&#x2010;2371.</Citation><ArticleIdList><ArticleId IdType="pubmed">18583543</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez&#x2010;Alcazar JA, Schneider E, Martinez MA, et al. Tumor necrosis factor&#x2010;alpha increases the steady&#x2010;state reduction of cytochrome b of the mitochondrial respiratory chain in metabolically inhibited L929 cells. J Biol Chem. 2000;275:13353&#x2010;13361.</Citation><ArticleIdList><ArticleId IdType="pubmed">10788444</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhan S, Cai GQ, Zheng A, et al. Tumor necrosis factor&#x2010;alpha regulates the hypocretin system via mRNA degradation and ubiquitination. Biochim Biophys Acta. 2011;1812:565&#x2010;571.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3042489</ArticleId><ArticleId IdType="pubmed">21094253</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark IA, Vissel B. Inflammation&#x2010;sleep interface in brain disease: TNF, insulin, orexin. J Neuroinflammation. 2014;11:51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3994460</ArticleId><ArticleId IdType="pubmed">24655719</ArticleId></ArticleIdList></Reference><Reference><Citation>Park KM, Yule DI, Bowers WJ. Tumor necrosis factor&#x2010;alpha potentiates intraneuronal Ca2+ signaling via regulation of the inositol 1,4,5&#x2010;trisphosphate receptor. J Biol Chem. 2008;283:33069&#x2010;33079.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2586262</ArticleId><ArticleId IdType="pubmed">18838384</ArticleId></ArticleIdList></Reference><Reference><Citation>Yirmiya R, Goshen I. Immune modulation of learning, memory, neural plasticity and neurogenesis. Brain Behav Immun. 2011;25:181&#x2010;213.</Citation><ArticleIdList><ArticleId IdType="pubmed">20970492</ArticleId></ArticleIdList></Reference><Reference><Citation>Keilp JG, Corbera K, Slavov I, Taylor MJ, Sackeim HA, Fallon BA. WAIS&#x2010;III and WMS&#x2010;III performance in chronic Lyme disease. J Int Neuropsychol Soc. 2006;12:119&#x2010;129.</Citation><ArticleIdList><ArticleId IdType="pubmed">16433951</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker JH, Lin JJ, Doernberg M, et al. Assessment of cognitive function in patients after COVID&#x2010;19 infection. JAMA Netw Open. 2021;4:e2130645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8536953</ArticleId><ArticleId IdType="pubmed">34677597</ArticleId></ArticleIdList></Reference><Reference><Citation>Tchessalova D, Posillico CK, Tronson NC. Neuroimmune activation drives multiple brain states. Front Syst Neurosci. 2018;12:39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6123349</ArticleId><ArticleId IdType="pubmed">30210310</ArticleId></ArticleIdList></Reference><Reference><Citation>Rankin LC, Artis D. Beyond host defense: emerging functions of the immune system in regulating complex tissue physiology. Cell. 2018;173:554&#x2010;567.</Citation><ArticleIdList><ArticleId IdType="pubmed">29677509</ArticleId></ArticleIdList></Reference><Reference><Citation>Bransfield RC. Neuropsychiatric Lyme Borreliosis: an overview with a focus on a specialty psychiatrist's clinical practice. Healthcare. 2018:6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6165408</ArticleId><ArticleId IdType="pubmed">30149626</ArticleId></ArticleIdList></Reference><Reference><Citation>Paterson RW, Brown RL, Benjamin L, et al. The emerging spectrum of COVID&#x2010;19 neurology: clinical, radiological and laboratory findings. Brain. 2020;143:3104&#x2010;3120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7454352</ArticleId><ArticleId IdType="pubmed">32637987</ArticleId></ArticleIdList></Reference><Reference><Citation>Baune BT, Wiede F, Braun A, Golledge J, Arolt V, Koerner H. Cognitive dysfunction in mice deficient for TNF&#x2010; and its receptors. Am J Med Genet B Neuropsychiatr Genet. 2008;147b:1056&#x2010;1064.</Citation><ArticleIdList><ArticleId IdType="pubmed">18286589</ArticleId></ArticleIdList></Reference><Reference><Citation>McAfoose J, Baune BT. Evidence for a cytokine model of cognitive function. Neurosci Behav Rev. 2009;34:615&#x2010;619.</Citation><ArticleIdList><ArticleId IdType="pubmed">18996146</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark IA, Alleva LM, Vissel B. The roles of TNF in brain dysfunction and disease. Pharmacol Ther. 2010;128:519&#x2010;548.</Citation><ArticleIdList><ArticleId IdType="pubmed">20813131</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin LY, Wu XF, Block ML, et al. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia. 2007;55:453&#x2010;462.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2871685</ArticleId><ArticleId IdType="pubmed">17203472</ArticleId></ArticleIdList></Reference><Reference><Citation>Haslberger A, Sayers T, Reiter H, Chung J, Sch&#xfc;tze E. Reduced release of TNF and PCA from macrophages of tolerant mice. Circ Shock. 1988;26:185&#x2010;192.</Citation><ArticleIdList><ArticleId IdType="pubmed">3197264</ArticleId></ArticleIdList></Reference><Reference><Citation>Matic M, Simon SR. Effects of gamma interferon on release of tumor necrosis factor&#x2010;alpha from lipopolysaccharide&#x2010;tolerant human monocyte&#x2010;derived macrophages. Infect Immun. 1992;60:3756&#x2010;3762.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC257387</ArticleId><ArticleId IdType="pubmed">1500186</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuno R, Wang J, Kawanokuchi J, Takeuchi H, Mizuno T, Suzumura A. Autocrine activation of microglia by tumor necrosis factor&#x2010;alpha. J Neuroimmunol. 2005;162:89&#x2010;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">15833363</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Zeng L, Yu T, et al. Positive feedback loop of autocrine BDNF from microglia causes prolonged microglia activation. Cell Physiol Biochem. 2014;34:715&#x2010;723.</Citation><ArticleIdList><ArticleId IdType="pubmed">25171395</ArticleId></ArticleIdList></Reference><Reference><Citation>Puntener U, Booth SG, Perry VH, Teeling JL. Long&#x2010;term impact of systemic bacterial infection on the cerebral vasculature and microglia. J Neuroinflammation. 2012;9:146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3439352</ArticleId><ArticleId IdType="pubmed">22738332</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang AC, Kern F, Losada PM, et al. Dysregulation of brain and choroid plexus cell types in severe COVID&#x2010;19. Nature. 2021;595:565&#x2010;571.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8400927</ArticleId><ArticleId IdType="pubmed">34153974</ArticleId></ArticleIdList></Reference><Reference><Citation>Pappata S, Levasseur M, Gunn RN, et al. Thalamic microglial activation in ischemic stroke detected in vivo by PET and [11C]PK1195. Neurology. 2000;55:1052&#x2010;1054.</Citation><ArticleIdList><ArticleId IdType="pubmed">11061271</ArticleId></ArticleIdList></Reference><Reference><Citation>Kooijman E, Nijboer CH, van Velthoven CT, et al. Long&#x2010;term functional consequences and ongoing cerebral inflammation after subarachnoid hemorrhage in the rat. PLoS One. 2014;9:e90584.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3946189</ArticleId><ArticleId IdType="pubmed">24603553</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramlackhansingh AF, Brooks DJ, Greenwood RJ, et al. Inflammation after trauma: microglial activation and traumatic brain injury. Ann Neurol. 2011;70:374&#x2010;383.</Citation><ArticleIdList><ArticleId IdType="pubmed">21710619</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi K, Zhang J, Dong JF, Shi FD. Dissemination of brain inflammation in traumatic brain injury. Cell Mol Immunol. 2019;16:523&#x2010;530.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6804599</ArticleId><ArticleId IdType="pubmed">30846842</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark IA. Background to new treatments for COVID&#x2010;19, including its chronicity, through altering elements of the cytokine storm. Rev Med Virol. 2020;20:203&#x2010;205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7883210</ArticleId><ArticleId IdType="pubmed">33580566</ArticleId></ArticleIdList></Reference><Reference><Citation>Jurgens HA, Amancherla K, Johnson RW. Influenza infection induces neuroinflammation, alters hippocampal neuron morphology, and impairs cognition in adult mice. J Neurosci. 2012;32:3958&#x2010;3968.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3353809</ArticleId><ArticleId IdType="pubmed">22442063</ArticleId></ArticleIdList></Reference><Reference><Citation>Elmore MR, Burton MD, Conrad MS, Rytych JL, Van Alstine WG, Johnson RW. Respiratory viral infection in neonatal piglets causes marked microglia activation in the hippocampus and deficits in spatial learning. J Neurosci. 2014;34:2120&#x2010;2129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3913866</ArticleId><ArticleId IdType="pubmed">24501353</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirschenberger M, Hunszinger V, Sparrer KMJ. Implications of innate immunity in post&#x2010;acute sequelae of non&#x2010;persistent viral Infections. Cells. 2021;10:2134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8391718</ArticleId><ArticleId IdType="pubmed">34440903</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi K, Tian DC, Li ZG, Ducruet AF, Lawton MT, Shi FD. Global brain inflammation in stroke. Lancet Neurol. 2019;18:1058&#x2010;1066.</Citation><ArticleIdList><ArticleId IdType="pubmed">31296369</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghezzi P, Dinarello CA, Bianchi M, Rosandich ME, Repine JE, White CW. Hypoxia increases production of interleukin&#x2010;1 and tumor necrosis factor by human mononuclear cells. Cytokine. 1991;3:189&#x2010;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">1883957</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q, Raoof M, Chen Y, et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature. 2010;464:41&#x2010;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2843437</ArticleId><ArticleId IdType="pubmed">20203610</ArticleId></ArticleIdList></Reference><Reference><Citation>Rrapaj E, Trisolini E, Bertero L, et al. Expression analysis of HMGB1 in histological samples of malignant pleural mesothelioma. Histopathology. 2018;72:1039&#x2010;1050.</Citation><ArticleIdList><ArticleId IdType="pubmed">29356044</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulze J, Zierath D, Tanzi P, et al. Severe stroke induces long&#x2010;lasting alterations of high&#x2010;mobility group box 1. Stroke. 2013;44:246&#x2010;248.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3530419</ArticleId><ArticleId IdType="pubmed">23204053</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugita A, Kinoshita K, Sakurai A, et al. Systemic impact on secondary brain aggravation due to ischemia/reperfusion injury in post&#x2010;cardiac arrest syndrome: a prospective observational study using high&#x2010;mobility group box 1 protein. Crit Care. 2017;21:247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5615459</ArticleId><ArticleId IdType="pubmed">28950909</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng P, Jyotaki M, Kim A, et al. Regulation of bitter taste responses by tumor necrosis factor. Brain Behav Immun. 2015;49:32&#x2010;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4567432</ArticleId><ArticleId IdType="pubmed">25911043</ArticleId></ArticleIdList></Reference><Reference><Citation>Sultan B, May LA, Lane AP. The role of TNF&#x2010;&#x3b1; in inflammatory olfactory loss. Laryngoscope. 2011;121:2481&#x2010;2486.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3540407</ArticleId><ArticleId IdType="pubmed">21882204</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufman A, Choo E, Koh A, Dando R. Inflammation arising from obesity reduces taste bud abundance and inhibits renewal. PLoS Biol. 2018;16:e2001959.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5860696</ArticleId><ArticleId IdType="pubmed">29558472</ArticleId></ArticleIdList></Reference><Reference><Citation>Tobinick E, Kim NM, Reyzin G, Rodriguez&#x2010;Romanacce H, DePuy V. Selective TNF inhibition for chronic stroke and traumatic brain injury: an observational study involving 629 consecutive patients treated with perispinal etanercept. CNS Drugs. 2012;26:1051&#x2010;1070.</Citation><ArticleIdList><ArticleId IdType="pubmed">23100196</ArticleId></ArticleIdList></Reference><Reference><Citation>Ralph SJ, Weissenberger A, Bonev V, et al. Phase I/II parallel double&#x2010;blind randomized controlled clinical trial of perispinal etanercept for chronic stroke: improved mobility and pain alleviation. Expert Opin Investig Drugs. 2020;29:311&#x2010;326.</Citation><ArticleIdList><ArticleId IdType="pubmed">31899977</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaishnavi S, Rao V, Fann JR. Neuropsychiatric problems after traumatic brain injury: unraveling the silent epidemic. Psychosomatics. 2009;50:198&#x2010;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">19567758</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu S, Duncan F, Anderson NH, Kuppuswamy A, Macloed MR, Mead GE. Exploratory cohort study of associations between serum C &#x2010; reactive protein and fatigue after stroke. PLoS One. 2015;10:e0143784.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4658028</ArticleId><ArticleId IdType="pubmed">26599129</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavadini G, Petrzilka S, Kohler P, et al. TNF alpha suppresses the expression of clock genes by interfering with E&#x2010;box&#x2010;mediated transcription. Proc Natl Acad Sci USA. 2007;104:12843&#x2010;12848.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1937554</ArticleId><ArticleId IdType="pubmed">17646651</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark I, Atwood C, Bowen R, Paz&#x2010;Filho G, Vissel B. Tumor necrosis factor&#x2010;induced cerebral insulin resistance in Alzheimer's disease links numerous treatment rationales. Pharmacol Rev. 2012;64:1004&#x2010;1026.</Citation><ArticleIdList><ArticleId IdType="pubmed">22966039</ArticleId></ArticleIdList></Reference><Reference><Citation>Delmotte P, Zavaletta VA, Thompson MA, Prakash YS, Sieck GC. TNF&#x3b1; decreases mitochondrial movement in human airway smooth muscle. Am J Physiol Lung Cell Mol Physiol. 2017;313:L166&#x2010;L176.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5538870</ArticleId><ArticleId IdType="pubmed">28473328</ArticleId></ArticleIdList></Reference><Reference><Citation>Delmotte P, Marin Mathieu N, Sieck GC. TNF&#x3b1; induces mitochondrial fragmentation and biogenesis in human airway smooth muscle. Am J Physiol Lung Cell Mol Physiol. 2021;320:L137&#x2010;L151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7847063</ArticleId><ArticleId IdType="pubmed">33146568</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakatomi Y, Mizuno K, Ishii A, et al. Neuroinflammation in patients with chronic fatigue syndrome/myalgic encephalomyelitis: An &#xb9;&#xb9;C&#x2010;(R)&#x2010;PK11195 PET Study. J Nucl Med. 2014;55:945&#x2010;950.</Citation><ArticleIdList><ArticleId IdType="pubmed">24665088</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherlinger M, Felten R, Gallais F, et al. Refining "Long&#x2010;COVID" by a Prospective Multimodal Evaluation of Patients with Long&#x2010;Term Symptoms Attributed to SARS&#x2010;CoV&#x2010;2 Infection. Infectious diseases and therapy, 2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8270770</ArticleId><ArticleId IdType="pubmed">34245450</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigal LH, Hassett AL. Commentary: &#x2018;What's in a name? That which we call a rose by any other name would smell as sweet'. Shakespeare W. Romeo and Juliet, II, ii(47&#x2013;48). Int J Epidemiol. 2005;34:1345&#x2010;1347.</Citation><ArticleIdList><ArticleId IdType="pubmed">16143662</ArticleId></ArticleIdList></Reference><Reference><Citation>Klit H, Finnerup NB, Jensen TS. Central post&#x2010;stroke pain: clinical characteristics, pathophysiology, and management. Lancet Neurol. 2009;8:857&#x2010;868.</Citation><ArticleIdList><ArticleId IdType="pubmed">19679277</ArticleId></ArticleIdList></Reference><Reference><Citation>Sommer C, Kress M. Recent findings on how proinflammatory cytokines cause pain: peripheral mechanisms in inflammatory and neuropathic hyperalgesia. Neurosci Lett. 2004;361:184&#x2010;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">15135924</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerard E, Spengler RN, Bonoiu AC, et al. Chronic constriction injury&#x2010;induced nociception is relieved by nanomedicine&#x2010;mediated decrease of rat hippocampal tumor necrosis factor. Pain. 2015;156:1320&#x2010;1333.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4474806</ArticleId><ArticleId IdType="pubmed">25851457</ArticleId></ArticleIdList></Reference><Reference><Citation>LaMacchia ZM, Spengler RN, Jaffari M, et al. Perispinal injection of a TNF blocker directed to the brain of rats alleviates the sensory and affective components of chronic constriction injury&#x2010;induced neuropathic pain. Brain Behav Immun. 2019;82:93&#x2010;105.</Citation><ArticleIdList><ArticleId IdType="pubmed">31376497</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark IA. Randomized controlled trial validating the use of perispinal etanercept to reduce post&#x2010;stroke disability has wide&#x2010;ranging implications. Expert Rev Neurother. 2020;20:203&#x2010;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">32028804</ArticleId></ArticleIdList></Reference><Reference><Citation>Tory HO, Zurakowski D, Sundel RP. Outcomes of children treated for Lyme arthritis: results of a large pediatric cohort. J Rheumatol. 2010;37:1049&#x2010;1055.</Citation><ArticleIdList><ArticleId IdType="pubmed">20360182</ArticleId></ArticleIdList></Reference><Reference><Citation>Studenic P, Radner H, Smolen JS, Aletaha D. Discrepancies between patients and physicians in their perceptions of rheumatoid arthritis disease activity. Arthritis Rheum. 2012;64:2814&#x2010;2823.</Citation><ArticleIdList><ArticleId IdType="pubmed">22810704</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopes F, Vicentini FA, Cluny NL, et al. Brain TNF drives post&#x2010;inflammation depression&#x2010;like behavior and persistent pain in experimental arthritis. Brain Behav Immun. 2020;89:224&#x2010;232.</Citation><ArticleIdList><ArticleId IdType="pubmed">32592863</ArticleId></ArticleIdList></Reference><Reference><Citation>Coiffier G, Tattevin P. Lyme disease: "End of the debate?". Joint Bone Spine. 2021;88:105181.</Citation><ArticleIdList><ArticleId IdType="pubmed">33812988</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunningham C, Maclullich AM. At the extreme end of the psychoneuroimmunological spectrum: delirium as a maladaptive sickness behaviour response. Brain Behav Immun. 2013;28:1&#x2010;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4157329</ArticleId><ArticleId IdType="pubmed">22884900</ArticleId></ArticleIdList></Reference><Reference><Citation>Caliendo MV, Kushon DJ, Helz JW. Delirium and Lyme disease. Psychosomatics. 1995;36:69&#x2010;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">7871138</ArticleId></ArticleIdList></Reference><Reference><Citation>Watne LO, Tonby K, Holten AR, Olasveengen TM, Romundstad LG, Neerland BE. Delirium is common in patients hospitalized with COVID&#x2010;19. Intern Emerg Med. 2021;16:1997&#x2010;2000.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8026811</ArticleId><ArticleId IdType="pubmed">33830418</ArticleId></ArticleIdList></Reference><Reference><Citation>Helms J, Kremer S, Merdji H, et al. Neurologic features in severe SARS&#x2010;CoV&#x2010;2 infection. N Engl J Med. 2020;382:2268&#x2010;2270.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7179967</ArticleId><ArticleId IdType="pubmed">32294339</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruneel F. Human cerebral malaria: 2019 mini review. Rev Neurol (Paris). 2019;175:445&#x2010;450.</Citation><ArticleIdList><ArticleId IdType="pubmed">31375284</ArticleId></ArticleIdList></Reference><Reference><Citation>Okumura A, Nakano T, Fukumoto Y, et al. Delirious behavior in children with influenza: its clinical features and EEG findings. Brain Dev. 2005;27:271&#x2010;274.</Citation><ArticleIdList><ArticleId IdType="pubmed">15862189</ArticleId></ArticleIdList></Reference><Reference><Citation>Klimiec&#x2010;Moskal E, Pasinska P, Kowalska K, et al. Elevated plasma levels of galectin&#x2010;3 binding protein are associated with post&#x2010;stroke delirium &#x2010; A pilot study. J Neuroimmunol. 2021;356:577579.</Citation><ArticleIdList><ArticleId IdType="pubmed">33901789</ArticleId></ArticleIdList></Reference><Reference><Citation>Maneewong J, Maneeton B, Maneeton N, et al. Delirium after a traumatic brain injury: predictors and symptom patterns. Neuropsychiatr Dis Treat. 2017;13:459&#x2010;465.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5317321</ArticleId><ArticleId IdType="pubmed">28243098</ArticleId></ArticleIdList></Reference><Reference><Citation>Parente D, Lu&#xed;s C, Veiga D, Silva H, Abelha F. Congestive heart failure as a determinant of postoperative delirium. Rev Port Cardiol. 2013;32:665&#x2010;671.</Citation><ArticleIdList><ArticleId IdType="pubmed">24011864</ArticleId></ArticleIdList></Reference><Reference><Citation>Su X, Meng ZT, Wu XH, et al. Dexmedetomidine for prevention of delirium in elderly patients after non&#x2010;cardiac surgery: a randomised, double&#x2010;blind, placebo&#x2010;controlled trial. Lancet. 2016;388:1893&#x2010;1902.</Citation><ArticleIdList><ArticleId IdType="pubmed">27542303</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark IA, Vissel B. The inflammatory nature of post&#x2010;surgical delirium predicts benefit of agents with anti&#x2010;TNF effects, such as Dexmedetomidine. Front Neurosci. 2018;12:257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5917006</ArticleId><ArticleId IdType="pubmed">29725287</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Qian Y. Protective role of dexmedetomidine in unmethylated CpG&#x2010;induced inflammation responses in BV2 microglia cells. Folia Neuropathol. 2016;54:382&#x2010;391.</Citation><ArticleIdList><ArticleId IdType="pubmed">28139820</ArticleId></ArticleIdList></Reference><Reference><Citation>Bransfield RC, Aidlen DM, Cook MJ, Javia S. A clinical diagnostic system for late&#x2010;stage neuropsychiatric lyme borreliosis based upon an analysis of 100 patients. Healthcare. 2020:8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7151210</ArticleId><ArticleId IdType="pubmed">31935905</ArticleId></ArticleIdList></Reference><Reference><Citation>Idro R, Kakooza&#x2010;Mwesige A, Balyejjussa S, et al. Severe neurological sequelae and behaviour problems after cerebral malaria in Ugandan children. BMC Res Notes. 2010;3:104.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2861066</ArticleId><ArticleId IdType="pubmed">20398391</ArticleId></ArticleIdList></Reference><Reference><Citation>Boubour A, Mboma S, V&#xf5; T, et al. "We can't handle things we don't know about": perceived neurorehabilitation challenges for Malawian paediatric cerebral malaria survivors. BMC Pediatr. 2020;20:503.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7607705</ArticleId><ArticleId IdType="pubmed">33138796</ArticleId></ArticleIdList></Reference><Reference><Citation>Shabani E, Ouma BJ, Idro R, et al. Elevated cerebrospinal fluid tumour necrosis factor is associated with acute and long&#x2010;term neurocognitive impairment in cerebral malaria. Parasite Immunol. 2017;39:e12438.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5492989</ArticleId><ArticleId IdType="pubmed">28453871</ArticleId></ArticleIdList></Reference><Reference><Citation>van Almenkerk S, Depla MF, Smalbrugge M, Eefsting JA, Hertogh CM. Institutionalized stroke patients: status of functioning of an under researched population. J Am Med Dir Assoc. 2012;13:634&#x2010;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">22705032</ArticleId></ArticleIdList></Reference><Reference><Citation>Bransfield RC. Suicide and Lyme and associated diseases. Neuropsychiatr Dis Treat. 2017;13:1575&#x2010;1587.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5481283</ArticleId><ArticleId IdType="pubmed">28670127</ArticleId></ArticleIdList></Reference><Reference><Citation>Sher L. Post&#x2010;COVID syndrome and suicide risk. QJM: Monthly J Ass Phys. 2021;114:95&#x2010;98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7928695</ArticleId><ArticleId IdType="pubmed">33486531</ArticleId></ArticleIdList></Reference><Reference><Citation>Wadhawan A, Stiller JW, Potocki E, et al. Traumatic brain injury and suicidal behavior: a review. J Alzheimers Dis. 2019;68:1339&#x2010;1370.</Citation><ArticleIdList><ArticleId IdType="pubmed">30909230</ArticleId></ArticleIdList></Reference><Reference><Citation>Nichter B, Maguen S, Monteith LL, et al. Factors associated with multiple suicide attempts in a nationally representative study of U.S. military veterans. J Psychiatr Res. 2021;140:295&#x2010;300.</Citation><ArticleIdList><ArticleId IdType="pubmed">34126423</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindqvist D, Wolkowitz OM, Mellon S, et al. Proinflammatory milieu in combat&#x2010;related PTSD is independent of depression and early life stress. Brain Behav Immun. 2014;42:81&#x2010;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">24929195</ArticleId></ArticleIdList></Reference><Reference><Citation>Eyre HA, Lavretsky H, Kartika J, Qassim A, Baune BT. Modulatory effects of antidepressant classes on the innate and adaptive immune system in depression. Pharmacopsychiatry. 2016;49:85&#x2010;96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5548302</ArticleId><ArticleId IdType="pubmed">26951496</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng T, Tripathi A, Pillai A. Inflammatory pathways in psychiatric disorders: the case of schizophrenia and depression. Curr Behav Neurosci Rep. 2020;7:128&#x2010;138.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8223755</ArticleId><ArticleId IdType="pubmed">34178573</ArticleId></ArticleIdList></Reference><Reference><Citation>Vardhana SA, Wolchok JD. The many faces of the anti&#x2010;COVID immune response. J Exp Med. 2020;217.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7191310</ArticleId><ArticleId IdType="pubmed">32353870</ArticleId></ArticleIdList></Reference><Reference><Citation>Kisand KE, Pr&#xfc;kk T, Kisand KV, L&#xfc;&#xfc;s SM, Kalbe I, Uibo R. Propensity to excessive proinflammatory response in chronic Lyme borreliosis. APMIS. 2007;115:134&#x2010;141.</Citation><ArticleIdList><ArticleId IdType="pubmed">17295680</ArticleId></ArticleIdList></Reference><Reference><Citation>Weissenbacher S, Ring J, Hofmann H. Gabapentin for the symptomatic treatment of chronic neuropathic pain in patients with late&#x2010;stage lyme borreliosis: a pilot study. Dermatology. 2005;211:123&#x2010;127.</Citation><ArticleIdList><ArticleId IdType="pubmed">16088158</ArticleId></ArticleIdList></Reference><Reference><Citation>Dias JM, de Brito TV, de Aguiar MD, et al. Gabapentin, a synthetic analogue of gamma aminobutyric acid, reverses systemic acute inflammation and oxidative stress in mice. Inflammation. 2014;37:1826&#x2010;1836.</Citation><ArticleIdList><ArticleId IdType="pubmed">24803298</ArticleId></ArticleIdList></Reference><Reference><Citation>Bao YH, Zhou QH, Chen R, et al. Gabapentin enhances the morphine anti&#x2010;nociceptive effect in neuropathic pain via the interleukin&#x2010;10&#x2010;heme oxygenase&#x2010;1 signalling pathway in rats. J Mol Neurosci. 2014;54:137&#x2010;146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4125805</ArticleId><ArticleId IdType="pubmed">24573601</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye L, Huang Y, Zhao L, et al. IL&#x2010;1beta and TNF&#x2010;alpha induce neurotoxicity through glutamate production: a potential role for neuronal glutaminase. J Neurochem. 2013;125:897&#x2010;908.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3747774</ArticleId><ArticleId IdType="pubmed">23578284</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeuchi H, Jin S, Wang J, et al. Tumor necrosis factor&#x2010;alpha induces neurotoxicity via glutamate release from hemichannels of activated microglia in an autocrine manner. J Biol Chem. 2006;281:21362&#x2010;21368.</Citation><ArticleIdList><ArticleId IdType="pubmed">16720574</ArticleId></ArticleIdList></Reference><Reference><Citation>Fine SM, Angel RA, Perry SW, et al. Tumor necrosis factor alpha inhibits glutamate uptake by primary human astrocytes &#x2010; implications for pathogenesis of HIV&#x2010;1 dementia. J Biol Chem. 1996;271:15303&#x2010;15306.</Citation><ArticleIdList><ArticleId IdType="pubmed">8663435</ArticleId></ArticleIdList></Reference><Reference><Citation>Conti F, Minelli A. Glutamate immunoreactivity in rat cerebral cortex is reversibly abolished by 6&#x2010;diazo&#x2010;5&#x2010;oxo&#x2010;L&#x2010;norleucine (DON), an inhibitor of phosphate&#x2010;activated glutaminase. J Histochem Cytochem. 1994;42:717&#x2010;726.</Citation><ArticleIdList><ArticleId IdType="pubmed">7910617</ArticleId></ArticleIdList></Reference><Reference><Citation>Potter MC, Baxter VK, Mathey RW, et al. Neurological sequelae induced by alphavirus infection of the CNS are attenuated by treatment with the glutamine antagonist 6&#x2010;diazo&#x2010;5&#x2010;oxo&#x2010;l&#x2010;norleucine. J Neurovirol. 2015;21:159&#x2010;173.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4375032</ArticleId><ArticleId IdType="pubmed">25645378</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio CC, Lin JW, Chang MW, et al. Therapeutic evaluation of etanercept in a model of traumatic brain injury. J Neurochem. 2010;115:921&#x2010;929.</Citation><ArticleIdList><ArticleId IdType="pubmed">20796174</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark IA. Editorial: an unsound AAN practice advisory on poststroke etanercept. Expert Rev Neurother. 2017;17:215&#x2010;217.</Citation><ArticleIdList><ArticleId IdType="pubmed">28081625</ArticleId></ArticleIdList></Reference><Reference><Citation>Batson OV. The function of the vertebral veins and their role in the spread of metastases. Ann Surg. 1940;112:138&#x2010;149.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1387927</ArticleId><ArticleId IdType="pubmed">17857618</ArticleId></ArticleIdList></Reference><Reference><Citation>Tobinick EL, Gross H, Weinberger A, Cohen H. TNF&#x2010;alpha modulation for treatment of Alzheimer's disease: A 6&#x2010; month pilot study. Med Gen Med Neurol Neurosurg. 2006;8:25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1785182</ArticleId><ArticleId IdType="pubmed">16926764</ArticleId></ArticleIdList></Reference><Reference><Citation>Tobinick E. Perispinal etanercept: a new therapeutic paradigm in neurology. Expert Rev Neurother. 2010;10:985&#x2010;1002.</Citation><ArticleIdList><ArticleId IdType="pubmed">20518613</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto PH, Gotow T, Ichimura T, et al. Visualization of the cerebrospinal fluid drainage into the Galen's vein. Arch Histol Jpn. 1985;48:173&#x2010;181.</Citation><ArticleIdList><ArticleId IdType="pubmed">4038002</ArticleId></ArticleIdList></Reference><Reference><Citation>Biceroglu H, Albayram S, Ogullar S, et al. Direct venous spinal reabsorption of cerebrospinal fluid: a new concept with serial magnetic resonance cisternography in rabbits. J Neurosurg Spine. 2012;16:394&#x2010;401.</Citation><ArticleIdList><ArticleId IdType="pubmed">22243405</ArticleId></ArticleIdList></Reference><Reference><Citation>Tobinick EL. Perispinal delivery of CNS drugs. CNS Drugs. 2016;30:469&#x2010;480.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4920856</ArticleId><ArticleId IdType="pubmed">27120182</ArticleId></ArticleIdList></Reference><Reference><Citation>Carpenter K, Decater T, Iwanaga J, et al. Revisiting the vertebral venous plexus&#x2010;A comprehensive review of the literature. World Neurosurg. 2021;145:381&#x2010;395.</Citation><ArticleIdList><ArticleId IdType="pubmed">33049379</ArticleId></ArticleIdList></Reference><Reference><Citation>Tobinick E, Vega CP. The cerebrospinal venous system: anatomy, physiology, and clinical implications. MedGenMed. 2006;8:53.</Citation><ArticleIdList><ArticleId IdType="pubmed">16915183</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen TS, Randall DC, Zolman JF. Protein accumulation in cerebrospinal fluid during &#x2010;90 degrees head&#x2010;down tilt in rabbit. J Appl Physiol. 1994;77:1081&#x2010;1086.</Citation><ArticleIdList><ArticleId IdType="pubmed">7836107</ArticleId></ArticleIdList></Reference><Reference><Citation>Tobinick EL, Chen K, Chen X. Rapid intracerebroventricular delivery of Cu&#x2010;DOTA&#x2010;etanercept after peripheral administration demonstrated by PET imaging. BMC Res Notes. 2009;2:28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2651903</ArticleId><ArticleId IdType="pubmed">19284700</ArticleId></ArticleIdList></Reference><Reference><Citation>Tobinick E. Rapid improvement of chronic stroke deficits after perispinal etanercept: three consecutive cases. CNS Drugs. 2011;25:145&#x2010;155.</Citation><ArticleIdList><ArticleId IdType="pubmed">21254790</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark IA. How diseases caused by parasites allowed a wider understanding of disease in general: my encounters with parasitology in Australia and elsewhere over the last 50 years. Internat J Parasitol. 2021;51:1265&#x2010;1276.</Citation><ArticleIdList><ArticleId IdType="pubmed">34757090</ArticleId></ArticleIdList></Reference><Reference><Citation>Meistrell ME, Botchkina GI, Wang HC, et al. Tumor necrosis factor is a brain damaging cytokine in cerebral ischemia. Shock. 1997;8:341&#x2010;348.</Citation><ArticleIdList><ArticleId IdType="pubmed">9361344</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbosa&#x2010;Silva MC, Lima MN, Battaglini D, et al. Infectious disease&#x2010;associated encephalopathies. Crit Care. 2021;25:236.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8259088</ArticleId><ArticleId IdType="pubmed">34229735</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinarello CA, Cannon JG, Wolff SM, et al. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med. 1986;163:1433&#x2010;1450.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2188124</ArticleId><ArticleId IdType="pubmed">3486936</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xc1;lvarez S, Mu&#xf1;oz&#x2010;Fern&#xe1;ndez M. TNF&#x2010;&#x391; may mediate inflammasome activation in the absence of bacterial infection in more than one way. PLoS One. 2013;8:e71477.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3737100</ArticleId><ArticleId IdType="pubmed">23940760</ArticleId></ArticleIdList></Reference><Reference><Citation>Brennan FM, Feldmann M. Cytokines in autoimmunity. Curr Opin Immunol. 1996;8:872&#x2010;877.</Citation><ArticleIdList><ArticleId IdType="pubmed">8994869</ArticleId></ArticleIdList></Reference><Reference><Citation>Charles P, Elliott MJ, Davis D, et al. Regulation of cytokines, cytokine inhibitors, and acute&#x2010;phase proteins following anti&#x2010;TNF&#x2010;alpha therapy in rheumatoid arthritis. J Immunol. 1999;163:1521&#x2010;1528.</Citation><ArticleIdList><ArticleId IdType="pubmed">10415055</ArticleId></ArticleIdList></Reference><Reference><Citation>Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin&#x2010;1 production in rheumatoid arthritis. Lancet. 1989;2:244&#x2010;247.</Citation><ArticleIdList><ArticleId IdType="pubmed">2569055</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler DM, Maini RN, Feldmann M, Brennan FM. Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF&#x2010;alpha antibody with the interleukin&#x2010;1 receptor antagonist. Eur Cytokine Netw. 1995;6:225&#x2010;230.</Citation><ArticleIdList><ArticleId IdType="pubmed">8789287</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorenz HM, Antoni C, Valerius T, et al. In vivo blockade of TNF&#x2010;alpha by intravenous infusion of a chimeric monoclonal TNF&#x2010;alpha antibody in patients with rheumatoid arthritis. Short term cellular and molecular effects. J Immunol. 1996;156:1646&#x2010;1653.</Citation><ArticleIdList><ArticleId IdType="pubmed">8568271</ArticleId></ArticleIdList></Reference><Reference><Citation>Nathan C. Secretory products of macrophages. J Clin Invest. 1987;79:319&#x2010;326.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC424063</ArticleId><ArticleId IdType="pubmed">3543052</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckley CD, Chernajovsky L, Chernajovsky Y, et al. Immune&#x2010;mediated inflammation across disease boundaries: breaking down research silos. Nat Immunol. 2021;22:1344&#x2010;1348.</Citation><ArticleIdList><ArticleId IdType="pubmed">34675389</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>